Director sold ~$1.01M of Arrowhead Pharmaceuticals
Automatic saleLoading…
ARWR · NASDAQ · Biotechnology
Biotechnology company based in Pasadena, California.
In the last 90 days, no insider of Arrowhead Pharmaceuticals reported an open-market purchase and 2 open-market sales worth about $1.19M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$62.35
Last 12 months
Not enough history
Market value
$8.81B
Revenue
$75.3M
+171.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$75.1M
This quarter −$181M, a year earlier −$157M
Net debt
—
Debt —, cash $54.8M, at Jun 30, 2026
Net income, last 12 months
−$320M
Operating profit covers interest -2.4x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 4, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
2 sales
$1.19M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$829M
+23258.2% vs the year before
Net income, fiscal 2025
−$1.63M
A loss for the year
Shares outstanding
141M
As of Jul 30, 2026
Director sold ~$1.01M of Arrowhead Pharmaceuticals
Automatic saleDirector sold ~$174K of Arrowhead Pharmaceuticals
Automatic saleDirector sold ~$228K of Arrowhead Pharmaceuticals
Scheduled in advanceOfficer sold ~$750K of Arrowhead Pharmaceuticals
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $37.50 on Oct 6, 2025 to $62.35 on Oct 5, 2026 (+66.3%). Disclosed activity in the last 12 months: 0 insider purchases, 64 insider sales (64 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.
6 active phase 3 trials and 6 active phase 2 trials led by this company, mostly in severe hypertriglyceridemia, obesity, homozygous familial hypercholesterolemia. The ones with the nearest registered primary completion date still ahead:
3 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.